The current "instruments and tools used to assess the value of cancer medicines may be too “blunt” to capture the true potential of future therapies and technologies to treat small patient populations, says a discussion paper released by Rare Cancers Australia. …
Latest Video
New Stories
-
Economics in the time of the COVID-19 pandemic
April 1, 2020 - - Comment -
Greg Hunt: New myeloma access headlines April listings
April 1, 2020 - - Latest News -
COVID-19: Pharmacy welcomes measures and MedAdvisor to launch telehealth
April 1, 2020 - - Latest News -
AusBiotech: Fast track refunds and scrap proposed cuts
April 1, 2020 - - Latest News -
ACCC grants wholesalers interim authorisation
March 31, 2020 - - Latest News -
Another extension to 'continued dispensing' arrangements
March 31, 2020 - - Latest News -
Nostradata: Demand for medicines almost doubled in just a few weeks
March 31, 2020 - - Latest News